Singapore Approves First Treatment for Liver Disease MASH
The Health Sciences Authority (HSA) in Singapore has officially approved the use of Wegovy® as a treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). This is a significant milestone, as it marks the first time a medication has been approved in Singapore specifically for this condition.
MASH is a serious liver disease that causes inflammation and damage to the liver. Over time, it can lead to liver fibrosis, which is the formation of scar tissue. If left untreated, this condition can progress to more severe health issues, including cirrhosis or liver failure.
Wegovy®, which contains the active ingredient semaglutide, is administered as a once-weekly injection. While it is already well-known for its use in weight management, its approval for MASH provides a new medical option for patients suffering from this specific liver condition.
Medical experts hope that this new treatment will help improve health outcomes for many people in Singapore. By managing the condition early, patients may be able to prevent further liver damage and improve their overall quality of life.
Patients who are concerned about their liver health are encouraged to speak with their doctors. A medical professional can provide more information on whether this treatment is suitable for their individual health needs.